Scientists have uncovered the genomic signature to explain why 18F-FDG imaging performs better than PSMA-targeted imaging for prostate cancer patients with low or no expression
Read more
(HealthDay)—African-American (AFR) men with prostate cancer have distinct genomic alterations from European-American (EUR) men, according to a study published online July 10 in Clinical Cancer
Read more
New research confirms the high impact of PSMA PET/CT in the detection and management of recurrent disease in prostate cancer patients. In initial results from
Read more
(HealthDay)—For men with advanced prostate cancer, the oral gonadotropin-releasing hormone (GnRH) antagonist relugolix maintains testosterone suppression compared with the GnRH agonist leuprolide, while enzalutamide is
Read more
(HealthDay)—Prostate cancer incidence rates decreased from 2005 to 2016 for local-stage disease among men aged ≥50 years but increased for regional- and distant-stage disease, according
Read more